Literature DB >> 8620413

Surgical indications for Ewing's sarcoma of the pelvis.

R S Yang1, J J Eckardt, F R Eilber, G Rosen, C A Forscher, F J Dorey, C M Kelly, R al-Shaikh.   

Abstract

BACKGROUND: Despite advances in adjuvant therapy, Ewing's sarcoma of the pelvis remains an anatomic site with a poor prognosis. This study evaluate the role of surgery in the management of patients with pelvic Ewing's sarcoma who also received conventional radiation therapy and chemotherapy.
METHODS: From May 1978 to February 1994, 19 patients with Stage IIB Ewing's sarcoma of the pelvis were treated at the UCLA Medical Center (Los Angeles, CA). There were eight lesions of the ilium, two of the sacrum, and nine involving two adjoining regions of pelvis. All patients received conventional medical management. The 19 patients were divided into two groups according to treatment modality. A group of 12 patients (Group A) had surgical resection, and their results were compared with those of another group of 7 patients (Group B) who did not have surgery.
RESULTS: The 5-year cumulative survival (Kaplan-Meier method) was 39% for all patients, 51% for Group A, and 18% for Group B. The 3-year cumulative survival was 59% for all patients, 72% for Group A, and 36% for Group B. Although the survival rate of Group A seemed better than that of Group B, the difference was not statistically significant (P = 0.093, log rank method). This study also suggested that, regardless of treatment modality, the outcome of patients with lesions involving two adjoining pelvic bones was poorer than that of those with a single lesion. In Group A, the 3-year cumulative survival rate for patients with single bone lesions (n = 8) was 86% and for patients with lesions involving two adjoining pelvic bones (n = 4) was 50% (P = 0.045, log rank method). Furthermore, the statistical analysis of the combined data of the single pelvic bone lesions in UCLA and that of Mayo Clinic series (n = 16 for surgery group and n = 15 for nonsurgery group) confirmed the better results for the surgical patients, which was consistent with the results from the Mayo Clinic with an even greater significance (P < 0.002).
CONCLUSION: This study demonstrates that surgery plus chemotherapy and radiation therapy is helpful for treating patients with pelvic Ewing's sarcoma so long as the tumor is limited to a single pelvic bone.

Entities:  

Mesh:

Year:  1995        PMID: 8620413     DOI: 10.1002/1097-0142(19951015)76:8<1388::aid-cncr2820760814>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Surgical classification of different types of en bloc resection for primary malignant sacral tumors.

Authors:  Dasen Li; Wei Guo; Xiaodong Tang; Tao Ji; Yidan Zhang
Journal:  Eur Spine J       Date:  2011-06-29       Impact factor: 3.134

2.  Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy.

Authors:  F S Mounessi; P Lehrich; U Haverkamp; N Willich; T Bölling; H T Eich
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

3.  Treatment of pelvic Ewing's sarcoma: Pros and cons of chemotherapy plus definitive radiotherapy versus surgery.

Authors:  İsmail Eralp Kaçmaz; Burçin Keçeci; Can Doruk Basa; Dündar Sabah
Journal:  Acta Orthop Traumatol Turc       Date:  2020-01       Impact factor: 1.511

Review 4.  Common musculoskeletal tumors of childhood and adolescence.

Authors:  Carola A S Arndt; Peter S Rose; Andrew L Folpe; Nadia N Laack
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

5.  Should Aggressive Surgical Local Control Be Attempted in All Patients with Metastatic or Pelvic Ewing's Sarcoma?

Authors:  Steven W Thorpe; Kurt R Weiss; Mark A Goodman; Alma E Heyl; Richard L McGough
Journal:  Sarcoma       Date:  2012-03-04

6.  CORR Insights®: Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

Authors:  Steven Gitelis
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

7.  Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis.

Authors:  Robert U Ashford; Eugene V McCloskey; O Prakash Purohit; Christine E Ingram; Robert J Grimer; Robert E Coleman
Journal:  Sarcoma       Date:  2002

8.  CT guided cryoablation for locally recurrent or metastatic bone and soft tissue tumor: initial experience.

Authors:  Michiro Susa; Kazutaka Kikuta; Robert Nakayama; Kazumasa Nishimoto; Keisuke Horiuchi; Sota Oguro; Masanori Inoue; Hideki Yashiro; Seishi Nakatsuka; Masaya Nakamura; Morio Matsumoto; Kazuhiro Chiba; Hideo Morioka
Journal:  BMC Cancer       Date:  2016-10-13       Impact factor: 4.430

9.  Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

Authors:  Dimosthenis Andreou; Andreas Ranft; Georg Gosheger; Beate Timmermann; Ruth Ladenstein; Wolfgang Hartmann; Sebastian Bauer; Daniel Baumhoer; Henk van den Berg; P D Sander Dijkstra; Hans Roland Dürr; Hans Gelderblom; Jendrik Hardes; Lars Hjorth; Justus Kreyer; Jarmila Kruseova; Andreas Leithner; Sergiu Scobioala; Arne Streitbürger; Per-Ulf Tunn; Eva Wardelmann; Reinhard Windhager; Heribert Jürgens; Uta Dirksen
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

10.  Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center.

Authors:  Wiebke K Guder; Jendrik Hardes; Markus Nottrott; Anne Juliane Steffen; Uta Dirksen; Arne Streitbürger
Journal:  J Orthop Surg Res       Date:  2020-11-16       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.